GLOBAL
Lumasiran is a subcutaneously administered RNAi therapeutic targeting hydroxyacid oxidase 1 (HAO1) – the gene encoding glycolate oxidase (GO) – for the treatment of primary hyperoxaluria type 1 (PH1). Where it is approved, it is marketed as OXLUMO™ (lumasiran).
Eligibility Requirements
To be eligible to seek access to lumasiran through the early access program (EAP), participants must meet certain requirements, including, but not limited to:
-
Patients of all ages with a documented diagnosis of PH1.
-
Not currently enrolled in another investigational device or drug study, or less than 30 days or 5 half-lives, whichever is longer, since ending another investigational device or drug study(s) or receiving other investigational agent(s)
-
Not previously dosed with lumasiran in a clinical study.
-
No history of liver transplant.
-
No medical conditions or comorbidities which, in the opinion of the physician, would interfere with Program compliance or the patient’s safety.
Only a licensed physician can request lumasiran. If you are a patient living in a country where lumasiran is not commercially available and are interested in seeking access to lumasiran through the early access program, please speak to your physician. Alnylam can only respond to a physician requesting access to lumasiran on behalf of a patient in his/her care.
If you are a physician who is seeking to obtain access to lumasiran for a patient in your care, please contact eap@alnylam.com
If you are a physician or patient and have a medical question, please contact medinfo@alnylam.com.
